Femasys Inc. FEMY PHARMA
Company Overview
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Why Investors Should Care
Revenue has grown at a 17.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.29M (+40.8% YoY); net profit $-18.63M.
- Trailing 12 Months Year-on-year growth — revenue -18.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.18% |
| 1 Year: | -18.90% |
Stock Price Performance
| 1 Year: | -82.51% |
| 6 Months: | -74.33% |
| 3 Months: | -50.28% |
| 1 Month: | +0.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.2% over 5 years.
CONS
- Trading 87.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FEMY Femasys Inc. PHARMA | 2.68 | -0.99 | $22.45M | 0.00% | -102.93% | - | 17.18% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.23K | 313.21K | 329.77K | 326.01K | 269.58K | 321.40K | 303.11K | 347.46K | 293.98K | 320.51K | 244.36K | 271.14K | 221.48K | 554.91K | 341.26K | 409.27K | 729.39K | 424.89K |
| Gross Profit | 127.96K | 222.77K | 236.73K | 218.38K | 164.18K | 198.73K | 200.76K | 216.00K | 188.86K | 210.04K | 158.18K | - | - | - | - | - | - | - |
| Operating Income | -1.48M | -1.56M | -1.83M | -1.90M | -2.25M | -2.88M | -2.66M | -3.06M | -3.04M | -2.94M | -4.08M | -3.46M | -4.48M | -5.12M | -5.46M | -3.85M | -3.65M | -4.22M |
| Net Income | -1.49M | -1.57M | -1.83M | -1.08M | -2.26M | -2.88M | -2.63M | -2.98M | -2.95M | -2.89M | -4.00M | -3.60M | -4.68M | -5.41M | -5.90M | -4.59M | -4.19M | 846.10K |
| Diluted EPS | -1.55 | -1.64 | -1.84 | -0.52 | -0.19 | -0.24 | -0.22 | -0.25 | -0.25 | -0.22 | -0.26 | -0.17 | -0.21 | -0.24 | -0.23 | -0.16 | -0.10 | 0.00 |
| R&D Expense | 888.70K | 995.62K | 995.02K | 894.87K | 1.14M | 1.42M | 1.47M | 1.65M | 1.54M | 1.53M | 2.07M | 1.77M | 1.98M | 2.30M | 2.97M | 1.41M | 1.38M | 1.31M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.04M | 1.18M | 1.21M | 1.07M | 1.63M | 2.29M |
| Gross Profit | 731.38K | 809.30K | 764.28K | - | - | - |
| Operating Income | -6.93M | -8.34M | -11.60M | -14.51M | -17.79M | -17.59M |
| Net Income | -6.91M | -7.54M | -11.39M | -14.25M | -18.82M | -18.63M |
| Diluted EPS | -7.20 | -1.12 | -0.96 | -0.93 | -0.85 | -0.47 |
| R&D Expense | 4.13M | 4.08M | 5.81M | 7.21M | 8.22M | 7.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.61M | 28.58M | 16.90M | 27.76M | 12.45M | 20.72M |
| Total Equity | -45.37M | -51.82M | 26.33M | 15.24M | 18.35M | 2.30M | 5.87M |
| Cash & Equivalents | - | 3.32M | 24.78M | 12.96M | 21.72M | 3.45M | 9.27M |
| Total Liabilities | - | 4.08M | 2.24M | 1.65M | 9.40M | 10.14M | 14.85M |
| Current Liabilities | - | 2.89M | 1.69M | 1.53M | 3.05M | 8.58M | 3.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.93M | -7.93M | -10.73M | -11.28M | -19.44M | -18.69M |
| Investing Cash Flow | 968.32K | -306.87K | -407.48K | -143.92K | -847.76K | -630.10K |
| Financing Cash Flow | 871.65K | 29.70M | -681.64K | 20.18M | 2.03M | 25.14M |
| Capital Expenditure | -8.35K | -306.87K | -407.48K | -143.92K | -761.71K | -525.01K |
| Free Cash Flow | -4.94M | -8.24M | -11.14M | -11.42M | -20.21M | -19.22M |
| Share Buybacks | - | - | 0 | 229.95K | 60.75K | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 70.5% | 68.6% | 63.4% | - | - | - |
| Operating Margin % | -668.0% | -706.7% | -961.7% | -1,353.4% | -1,091.8% | -767.0% |
| Net Margin % | -666.2% | -639.0% | -944.6% | -1,329.1% | -1,155.0% | -812.3% |
| ROE % | 13.3% | -28.6% | -74.8% | -77.6% | -816.5% | -317.4% |
| ROCE % | -147.0% | -31.0% | -75.5% | -58.7% | -460.5% | -102.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dauntless Investment Group, LLC | 22.30% | 1.87M | $4.84M |
| 2 | Vanguard Capital Management LLC | 0.74% | 62.23K | $161.18K |
| 3 | Jane Street Group, LLC | 0.63% | 52.51K | $136.00K |
| 4 | Geode Capital Management, LLC | 0.37% | 30.92K | $80.08K |
| 5 | UBS Group AG | 0.22% | 18.78K | $48.63K |
| 6 | Citadel Advisors Llc | 0.20% | 16.92K | $43.83K |
| 7 | Vanguard Fiduciary Trust Co | 0.15% | 12.49K | $32.35K |
| 8 | Osaic Holdings Inc. | 0.03% | 2.40K | $6.21K |
| 9 | Blackrock Inc. | 0.02% | 1.78K | $4.62K |
| 10 | IFP Advisors, Inc | 0.01% | 1.05K | $2.72K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FEMY
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5yRnk2aTNUMXRpMldXdW1VUDRSYlRqWUZYRU12RTRvbjF0X0x3ZnNsV29lTzdDOEpKSm1VaVdwdExWYmdyM2txNw?oc=5" target="_blank">Femasys Stock Price Forecast. Should You Buy FEMY?</a> <fo…
FEMASYS INC (FEMY) Stock Price & Overview - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5EQ0wyX1hwVnlxQ19kbFdhZV9XWGh3NnE3M2JoUlBFTEhQTzFBN2JSZ202OEw0NnV5WVQyWTNMVHE3LUliWWR2Vy1nWkJKejNFVmt2RzVsc0R0RDVsOEhv?oc=5" target="_blank">FEMASYS INC (FEMY) Stock Price & Overvi…
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxPd0VPbmFwQktUSHRUOEt0MzBPUlBmcU1KeE9EVUZtak80SEFoa2h2LXFPcExwemZTR3lZRzBlbmUxd010R2MxVGRjX0dDV2pBamE3WEZsMXd6ZmxKU1RNZVYtRzNZYTF0eUVHR2RkekRfUWpDNXM1UDc0RDE0cWhNa2VjNXJRVnh2ekJRNk…
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOSWJyd1hueFpZZGlEYXBRN0VKOTJTek4xYjVQeGoyZ2ZVcXlQdXI1OUZ4cVoyX3h6ODZMdFlSZElMUGVDSDlJYXlFMk1wOFZqU05zcWxfZkxnSkdsSm1DUFRkU0Y1aVExOE9LWjVKOFBsYjFDblEyVHo0X3dleF9PUGRKaUFza21JNmZrZD…
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQd2EwTW50bmdrUkI3UGE5bUg5TjlpQjhHZkhCRVNiLUhCSzcxNTBxQV9ZTFVhMGpORDdwZjdvMXVGejRFYjdRekJjVXRGUzBCZXptdml3dk1lVW83YjBlM1pNaHl6T1R2RTVWTmtfcXBJMlh1ZUdtdWpQMXgtU25maVhnNWVBa1FIMHYxTE…
$FEMY stock is up 22% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbTRaclhnd2c5bUk1dUdFOGFDcnJaVktfYm9PM0h5NlZvRUhLZGhadnQzSHpaek44ZC1MOU1oTEpmOFF1el9IZUZmd2lRSGF2c2FORi1UdFJLdVhaYzNmWW5XUUhtZldpT0x5R3hIbEVjaUpCQW8tWmFoN1gyMTZPWWkzbnJ1X2pqamtJTj…
FEMY — Frequently Asked Questions
What is the current share price of Femasys Inc. (FEMY)?
As of 2026-09-19 21:16 PDT, Femasys Inc. (FEMY) trades at $2.68 on NasdaqCM. Its 52-week range is $2.16 to $20.80.
What is the market capitalisation of FEMY?
Femasys Inc. (FEMY) has a market capitalisation of $22.45M on NasdaqCM.
What is the P/E ratio of FEMY?
FEMY trades at a trailing price-to-earnings (P/E) ratio of -0.99. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.12.
Is FEMY a good stock to buy?
This page provides a data-driven analysis of Femasys Inc. (FEMY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.